Pacific Biosciences of California (NASDAQ:PACB) Raised to “Hold” at Wall Street Zen

Pacific Biosciences of California (NASDAQ:PACB) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Other analysts have also recently issued reports about the stock. Barclays boosted their price objective on shares of Pacific Biosciences of California from $1.25 to $2.00 and gave the company an “underweight” rating in a research note on Thursday. Piper Sandler reaffirmed a “neutral” rating and issued a $3.00 target price (up from $2.00) on shares of Pacific Biosciences of California in a research report on Thursday. UBS Group started coverage on Pacific Biosciences of California in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $1.35 target price on the stock. Finally, Weiss Ratings upgraded Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 13th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $2.09.

Pacific Biosciences of California Stock Performance

PACB opened at $2.26 on Friday. The company’s 50 day simple moving average is $1.93 and its 200 day simple moving average is $1.62. Pacific Biosciences of California has a 1 year low of $1.07 and a 1 year high of $3.43. The stock has a market capitalization of $702.48 million, a PE ratio of -5.38 and a beta of 2.21.

Pacific Biosciences of California (NASDAQ:PACB) last issued its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. The firm had revenue of $40.56 million during the quarter, compared to analyst estimates of $39.31 million. Pacific Biosciences of California had a negative net margin of 81.31% and a negative return on equity of 5,752.12%. As a group, sell-side analysts expect that Pacific Biosciences of California will post -0.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Pacific Biosciences of California news, insider Mark Van Oene sold 26,911 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1.13, for a total transaction of $30,409.43. Following the completion of the sale, the insider directly owned 2,705,853 shares in the company, valued at $3,057,613.89. The trade was a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James R. Gibson II sold 661,815 shares of the business’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $3.11, for a total transaction of $2,058,244.65. Following the sale, the insider owned 1,083,848 shares of the company’s stock, valued at approximately $3,370,767.28. This represents a 37.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pacific Biosciences of California

A number of hedge funds have recently made changes to their positions in the business. Hhlr Advisors LTD. acquired a new stake in Pacific Biosciences of California in the 2nd quarter valued at $1,544,000. BlackRock Inc. purchased a new position in Pacific Biosciences of California in the second quarter valued at about $54,330,000. Bank of America Corp DE acquired a new position in shares of Pacific Biosciences of California during the second quarter worth about $2,265,000. Bank of New York Mellon Corp acquired a new position in shares of Pacific Biosciences of California during the second quarter worth about $1,290,000. Finally, Man Group plc acquired a new position in shares of Pacific Biosciences of California during the second quarter worth about $1,004,000.

More Pacific Biosciences of California News

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: PacBio reported third-quarter revenue of $40.56 million, above the $39.31 million consensus, and a loss of $0.11 per share, narrower than the expected $0.13 loss. Coverage also highlighted clinical adoption and AI partnerships as sources of growth. Zacks Q3 results Q3 deep dive
• Positive Sentiment: Piper Sandler reaffirmed its Neutral rating but raised its price target to $3 from $2, indicating a more favorable valuation view. Piper Sandler rating
• Neutral Sentiment: The company announced CFO changes; the report provided no further detail on the transition’s expected impact. CFO changes
• Negative Sentiment: Management narrowed its 2026 revenue guidance to $155 million–$160 million. Analysts also pointed to falling gross margins and substantial cash burn, which raises concerns about the company’s financial position despite its target of cash-flow breakeven in 2028. Revenue guidance and breakeven target Q3 outlook analysis
• Negative Sentiment: Barclays lifted its price target to $2 from $1.25 but maintained an Underweight rating, signaling continued caution about the shares. Barclays rating

About Pacific Biosciences of California

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.